| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/20/2005 | CA2262523C Medical devices comprising ionically and non-ionically cross-linked polymer hydrogels having improved mechanical properties |
| 09/20/2005 | CA2217238C Cross-linked cellulose as a tablet excipient |
| 09/20/2005 | CA2151604C Application of riluzole in the treatment of neurological lesions associated with traumas |
| 09/20/2005 | CA2089494C Vesicles in non-polar media |
| 09/15/2005 | WO2005084786A1 Water containing oxygen nano bubbles and method for production thereof |
| 09/15/2005 | WO2005084725A1 Compositions for repairing bone and methods for preparing and using such compositions |
| 09/15/2005 | WO2005084710A2 Nanocell drug delivery system |
| 09/15/2005 | WO2005084705A1 Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| 09/15/2005 | WO2005084703A1 Sustained-release composition for oral cavity |
| 09/15/2005 | WO2005084688A1 An injection power containing vermifuge |
| 09/15/2005 | WO2005084685A2 Boronate medicaments suitable for short duration anticoagulation |
| 09/15/2005 | WO2005084681A1 Composition for increasing levels of hormones and a method for preparation of said composition |
| 09/15/2005 | WO2005084676A1 Pharmaceutical preparation containing tolperisone with controlled release of active substances for oral administration |
| 09/15/2005 | WO2005084670A1 Pharmaceutical formulation |
| 09/15/2005 | WO2005084669A1 Pharmaceutical composition |
| 09/15/2005 | WO2005084650A1 Pharmaceutical composition for topical use in form of xerogels or films and methods for production |
| 09/15/2005 | WO2005084649A1 Stable capsule preparation |
| 09/15/2005 | WO2005084648A1 Pharmaceutical compositions comprising candesartan cilexetil |
| 09/15/2005 | WO2005084647A1 Pharmaceutical composition comprising pimobendan |
| 09/15/2005 | WO2005084646A1 Powdered compositions of sensitive active materials in an at least partially amorphous state |
| 09/15/2005 | WO2005084645A1 Embolic particles |
| 09/15/2005 | WO2005084644A1 Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, dna vaccination and administration of gene based drugs |
| 09/15/2005 | WO2005084643A1 Crystalline composition containing escitalopram oxalate |
| 09/15/2005 | WO2005084642A1 Apoprotein cochleate compositions |
| 09/15/2005 | WO2005084641A1 Method and apparatus for producing carrier complexes |
| 09/15/2005 | WO2005084640A1 Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| 09/15/2005 | WO2005084639A2 Polymeric drug delivery system for hydrophobic drugs |
| 09/15/2005 | WO2005084638A2 Formulations decreasing infectivity of pulmonary diseases |
| 09/15/2005 | WO2005084637A2 Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof |
| 09/15/2005 | WO2005084636A2 A process for the preparation of controlled-release pharmaceutical composition of metoprolol |
| 09/15/2005 | WO2005084635A2 Pharmaceutical ocular preparations suitable for the treatment of the ocular surface and related disorders/diseases |
| 09/15/2005 | WO2005084634A1 Delivery systems for non-steroidal anti-inflammatory drugs (nsaids) |
| 09/15/2005 | WO2005084632A1 Method and composition for burned skin |
| 09/15/2005 | WO2005084581A1 Medical three-dimensional structure, process for producing the same and production apparatus |
| 09/15/2005 | WO2005084307A2 Use of lipid conjugates in the treatment of disease |
| 09/15/2005 | WO2005084273A2 Method and apparatus for automatically modifying delivery profile of drug delivry system |
| 09/15/2005 | WO2005061552A8 Amphiphilic heparin derivative formed by coupling a heparin with a bile acid |
| 09/15/2005 | WO2005060361A3 Pharmaceutical formulations for itraconazole |
| 09/15/2005 | WO2005055977A3 Form of administration for controlling primary headaches |
| 09/15/2005 | WO2005053612A3 Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
| 09/15/2005 | WO2005048996A3 Modified release dosage forms of skeletal muscle relaxants |
| 09/15/2005 | WO2005048731A3 Lecithin-containing granular compositions and methods of their preparation |
| 09/15/2005 | WO2005042054A3 Pretreatment method and system for enhancing transdermal drug delivery |
| 09/15/2005 | WO2005041922A3 Composition |
| 09/15/2005 | WO2005040195A3 Formulation of exendins |
| 09/15/2005 | WO2005032521A3 Non-flammable topical anesthetic liquid aerosols |
| 09/15/2005 | WO2005023181B1 Polymeric systems for controlled drug therapy |
| 09/15/2005 | WO2005020900A3 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 09/15/2005 | WO2005016256A3 Hemostatic compositions containing sterile thrombin |
| 09/15/2005 | WO2005004895A3 Compositions and methods for enhanced mucosal delivery of growth hormone |
| 09/15/2005 | WO2005002541A3 Process for preparing formulations of lipid-regulating drugs |
| 09/15/2005 | WO2004110493A3 Method of pulmonary administration of an agent |
| 09/15/2005 | WO2004108117A3 Extended release osmo-microsealed formulation comprising venlafaxine |
| 09/15/2005 | WO2004103260A3 Ternary and quaternary eutectic mixtures. |
| 09/15/2005 | WO2004100924A3 Method of preparing a formulation containing a microdosed active principle |
| 09/15/2005 | WO2004093793A3 Delivery vehicle for silver ions |
| 09/15/2005 | WO2004078092A3 Cream dispenser |
| 09/15/2005 | WO2004060352A8 Non-hygroscopic formulation comprising a hydroscopic drug |
| 09/15/2005 | WO2004054553A9 Transdermal buprenorphine dosage regimen for analgesia |
| 09/15/2005 | US20050203635 Soft tissue implants and anti-scarring agents |
| 09/15/2005 | US20050203482 Pharmaceutical dispensing apparatus and method |
| 09/15/2005 | US20050203270 polymer of the formula I:** Image-1wherein: Z is O or NH ;R1 represents a non-functional backbone of a hydroxy acid or amino acid derived from a cyclic ester or diester or cyclic amide or diamide monomer (A);R2 represents a non-functional chain derived from an epoxide monomer (B), said chain ending |
| 09/15/2005 | US20050203187 Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof |
| 09/15/2005 | US20050203186 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release |
| 09/15/2005 | US20050203175 Ethanol, Glycerol formal, Water, Methyl-parahydroxy benzoate and Propyl-parahydroxy benzoate; analgesic, antipyretic, antiinflammatory |
| 09/15/2005 | US20050203165 Perfectly reproducible crystalline form that especially exhibits valuable characteristics for formulation of inhibitors of angiotensin I converting enzyme; preparation from a solution of the salt in CH2Cl2 or ethyl acetate; treating cardiovascular disease |
| 09/15/2005 | US20050203154 Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 09/15/2005 | US20050203125 Treating pseudobulbar affect or emotional lability; nervous system, brain, and neurodegenerative disorders; analgesics; neuropathic pain; dextromethorphan hydrobromide and quinidine sulfate |
| 09/15/2005 | US20050203122 Benzenesulfonic acid salts of clopidogrel, methods for preparing same, and pharmaceutical formulations thereof |
| 09/15/2005 | US20050203097 Pharmaceutical composition comprising pimobendan |
| 09/15/2005 | US20050203055 Administering an effective amount of a sulfated polysaccharide for therapy and prophylaxis of fungal infection |
| 09/15/2005 | US20050203032 Mannose phosphate and salts, for increasing vaginal cell growth in a mammal |
| 09/15/2005 | US20050203017 For activating the non-proteolytically activated thrombin receptor |
| 09/15/2005 | US20050203002 Sustained release compositions for delivery of pharmaceutical proteins |
| 09/15/2005 | US20050203000 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection |
| 09/15/2005 | US20050202983 Mono, di, oligo or polysaccharide solutions useful in the manufacture of gentle ophthalmic products that prevent tissue irritation; for topical application; solution, suspension, gel or ointment; contact lens care solution containing above carbohydrates |
| 09/15/2005 | US20050202096 Photocrosslinkable; permeable membrane; stem cell scaffolds; drug delivery |
| 09/15/2005 | US20050202095 Rotor-stator apparatus and process for the formation of particles |
| 09/15/2005 | US20050202094 Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
| 09/15/2005 | US20050202093 Prolonged suppression of electrical activity in excitable tissues |
| 09/15/2005 | US20050202092 Process for the preparation of crystalline nano-particle dispersions |
| 09/15/2005 | US20050202091 Stable pharmaceutical composition comprising erythropoietin |
| 09/15/2005 | US20050202090 Novel pharmaceutical dosage forms and method for producing same |
| 09/15/2005 | US20050202089 Sustained-release pharmaceutical formulations containing mizolastine |
| 09/15/2005 | US20050202088 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof |
| 09/15/2005 | US20050202087 Combining alpha -dihydroergocryptine with a p hydrophilic swelling agent of hydroxyalkylcelluloses, polyvinyl alcohols, polyoxyethylene glycols, carbomers, poloxamers and excipients; improving bioavailability |
| 09/15/2005 | US20050202086 Lactose monohydrate, copovidon, hypromellose, and lubricant of magnesium stearate or anhydrous colloidal silica |
| 09/15/2005 | US20050202084 Pharmaceutical compositions |
| 09/15/2005 | US20050202083 Storage stable tablets of fosinopril sodium |
| 09/15/2005 | US20050202082 Press-coated molded article undergoing quick disintegration |
| 09/15/2005 | US20050202081 Stable pharmaceutical compositions comprising ace inhibitor(s) |
| 09/15/2005 | US20050202080 Mixing the salt or free base of the active pharmaceutical ingredient, tannic acid, and an anti-clumping agent to form a powder tannate salt complex; adding a liquid to the powder mixture to form a moistened blend; forming tablet, capsule or other solid dosage forms |
| 09/15/2005 | US20050202079 Nitrofurantoin monohydrate, sodium alginate, alginic acid and hypromellose in controlled release form; macrocrystalline nitrofurantoin in immediate release form; bacterial infection |
| 09/15/2005 | US20050202078 Long-circulating microvesicles with steroid hormones; microvesicles have an interaction with macrophages in the tumor, cell type could be down-regulated in tumor therapy, liberating the encapsulated corticosteroids to allow interaction with other cell types in and around the tumor |
| 09/15/2005 | US20050202077 Targeted delivery of RNA interference molecules |
| 09/15/2005 | US20050202076 Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes |
| 09/15/2005 | US20050202075 Liposome with an internal compartment; a gene encoding a short hairpin RNA, within the internal compartment of the liposome; receptors targeting agents; conjugation agents connecting targeting agents to the exterior surface of liposome via conjugation agents |
| 09/15/2005 | US20050202074 Method of administering liposomal encapsulated taxane |
| 09/15/2005 | US20050202073 Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
| 09/15/2005 | US20050202072 Dry mouldable drug formulation |